Emergent BioSolutions Reports First Quarter 2024 Financial Results
01 mai 2024 16h57 HE
|
Emergent BioSolutions
First Quarter 2024 Total Revenues of $300.4 million, above the prior guidance rangeFirst Quarter 2024 Net Income of $9.0 million and Adjusted EBITDA of $66.9 millionUpdates FY 2024 guidance ...
Emergent BioSolutions Announces Strategic Operational Changes to Stabilize Financial Position
01 mai 2024 16h10 HE
|
Emergent BioSolutions
Proactive changes aim to ensure long-term sustainability and growth, optimize operations, streamline processes, and allocate resources more efficientlyReorganization will align with evolving business...
Emergent BioSolutions Releases New Survey Findings Underscoring the Need to Continue Expanding Access & Increasing Awareness to Naloxone
01 mai 2024 11h03 HE
|
Emergent BioSolutions
Nearly 9 in 10 Americans surveyed agree opioid overdoses are a concern for teenagers and college students; parents in the survey want life-saving treatment to be easily accessible in case of an...
Emergent BioSolutions Announces Amendment to its Existing Credit Facility
30 avr. 2024 17h26 HE
|
Emergent BioSolutions
GAITHERSBURG, Md., April 30, 2024 (GLOBE NEWSWIRE) -- Emergent BioSolutions Inc. (NYSE: EBS) announced that it has entered into a “Consent, Waiver and Seventh Amendment” to its existing credit...
Emergent BioSolutions to Release First Quarter 2024 Financial Results & Conduct Conference Call on May 1, 2024
22 avr. 2024 08h05 HE
|
Emergent BioSolutions
GAITHERSBURG, Md., April 22, 2024 (GLOBE NEWSWIRE) -- Emergent BioSolutions Inc. (NYSE: EBS) will host a conference call on Wednesday, May 1, 2024, at 5:00 pm eastern time to discuss the financial...
Emergent BioSolutions Continues to Broaden Access, Awareness and Availability of NARCAN® Nasal Spray to Help Save Lives from the Ongoing Opioid Crisis
28 mars 2024 08h15 HE
|
Emergent BioSolutions
As the first-ever U.S. Food and Drug Administration (FDA) approved over-the-counter (OTC) naloxone in 2023, Emergent is working to expand access with NARCAN® Nasal Spray and build on its longstanding...
Emergent BioSolutions Receives NAI Status for Baltimore Bayview Manufacturing Facility
25 mars 2024 08h05 HE
|
Emergent BioSolutions
GAITHERSBURG, Md., March 25, 2024 (GLOBE NEWSWIRE) -- Emergent BioSolutions Inc. (NYSE: EBS) announced that the U.S. Food and Drug Administration (FDA) has listed “No Action Indicated” or NAI status...
Emergent BioSolutions Reports Fourth Quarter 2023 Financial Results
06 mars 2024 16h31 HE
|
Emergent BioSolutions
Fourth Quarter 2023 Total Revenues of $277 million, which aligned our Full Year to the mid-point of guidanceFull Year 2023 Total Revenues of $1.05 billion, which was the mid-point of guidanceFourth...
Emergent BioSolutions to Release Fourth Quarter & Full Year 2023 Financial Results, and Conduct Conference Call on March 6, 2024
29 févr. 2024 07h00 HE
|
Emergent BioSolutions
GAITHERSBURG, Md., Feb. 29, 2024 (GLOBE NEWSWIRE) -- Emergent BioSolutions Inc. (NYSE: EBS) will host a conference call on Wednesday, March 6, 2024, at 5:00 pm eastern time to discuss the...
Emergent BioSolutions Appoints Industry Leader Joseph C. Papa as New President and CEO
21 févr. 2024 07h00 HE
|
Emergent BioSolutions
Papa will lead Emergent into a new era of focusing on protecting public health, returning to growth and paying down the company’s debt GAITHERSBURG, Md., Feb. 21, 2024 (GLOBE NEWSWIRE) -- Emergent...